NASDAQ
2.00USD
-0.19 (-8.68%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
43.7M
P/E
—
EPS
—
Beta
0.21
52W range
2-11.88
Day range
2.00–2.29
Open
2.27
Prev close
2.19
Volume
58.4K
Avg volume
201.2K
Dividend
0.00
IPO
2020-07-30
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Kalaris Therapeutics Inc — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for KLRS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
